Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue to be challenging at both the patient and programme level. The World Health Organization (WHO) estimated 480 000 new cases of MDR-TB in 2015 and an additional 100 000 cases diagnosed with rifampicin-resistant T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2017-03, Vol.49 (3), p.1700146-1700146
Hauptverfasser:	Pontali, Emanuele, D'Ambrosio, Lia, Centis, Rosella, Sotgiu, Giovanni, Migliori, Giovanni Battista
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - therapeutic use Diarylquinolines - therapeutic use Drug resistance Humans Multidrug resistance Multidrug resistant organisms Mycobacterium Practice Guidelines as Topic Rifampin Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy World Health Organization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue to be challenging at both the patient and programme level. The World Health Organization (WHO) estimated 480 000 new cases of MDR-TB in 2015 and an additional 100 000 cases diagnosed with rifampicin-resistant TB (RR-TB). India, China and the Russian Federation accounted for almost half (45%) of the total burden [1]. Out of 580 000 patients eligible for MDR-TB treatment, only 125 000 (20%) were enrolled in treatment programmes [1].
ISSN:	0903-1936 1399-3003
DOI:	10.1183/13993003.00146-2017